To further validate the therapeutic potential of ferroptosis induction against RB1-deficient prostate cancer, we performed in vivo preclinical studies of JKE-1674 in prostate epithelium-specific Pten/Rb1 double-knockout mice, with prostate tumors that were lineage traced by a bright and stable RFP (subsequently referred to as PPR-RFP mice). The gene discussed is RB1; the disease is prostate carcinoma.